Biocardia Announces Interim Efficacy Results In Phase 3 CardiAMP Cell Therapy Heart Failure Trial; For The First-tier, All-cause Death At 12 Months There Were 5.6% Versus 5.3% In The Control Group (P = 0.42)
Portfolio Pulse from Benzinga Newsdesk
Biocardia has announced interim efficacy results for its Phase 3 CardiAMP Cell Therapy Heart Failure Trial. The first-tier, all-cause death at 12 months was 5.6%, compared to 5.3% in the control group, a difference that was not statistically significant (P = 0.42).
September 05, 2023 | 11:20 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Biocardia's Phase 3 trial results show no significant difference in all-cause death at 12 months compared to the control group. This could potentially impact investor sentiment.
The results of clinical trials can significantly impact a biotech company's stock price. In this case, the lack of a significant difference in all-cause death at 12 months compared to the control group in Biocardia's Phase 3 trial may not be seen as positive news by investors, potentially leading to a neutral or negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100